Hematopoietic stem cell transplantation for aplastic anemia and paroxysmal nocturnal hemoglobinuria: current evidence and recommendations

References

• Young NS. Acquired aplastic anemia. In: Young NS, editor. Bone marrow failure syndromes. Philadelphia: WB Saunders; 2000. 1-46
   Google Scholar
• Young NS, Maciejewski J. The pathophysiology of acquired aplastic anemia. N Engl J Med 1997;336:1365-72
   PubMed Web of Science ®Google Scholar
• Calado RT. Telomeres and marrow failure. Hematology Am Soc Hematol Educ Program 2009;2009:338-43
   Google Scholar
• Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006;108:2509-19
   PubMed Web of Science ®Google Scholar
• Risitano AM, Maciejewski JP, Green S, et al. In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing. Lancet 2004;364:355-64
   PubMed Web of Science ®Google Scholar
• Sato T, Selleri C, Anderson S, et al. Expression and modulation of cellular receptors for interferon-gamma, tumour necrosis factor, and Fas on human bone marrow CD34+ cells. Br J Haematol 1997;97:356-65
   PubMed Web of Science ®Google Scholar
• Maciejewski J, Selleri C, Anderson S, Young NS. Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood 1995;85:3183-90
   PubMed Web of Science ®Google Scholar
• Selleri C, Maciejewski JP, Sato T, Young NS. Interferon-gamma constitutively expressed in the stromal microenvironment of human marrow cultures mediates potent hematopoietic inhibition. Blood 1996;87:4149-57
   PubMed Web of Science ®Google Scholar
• Dufour C, Corcione A, Svahn J, et al. Interferon gamma and tumour necrosis factor alpha are overexpressed in bone marrow T lymphocytes from paediatric patients with aplastic anaemia. Br J Haematol 2001;115:1023-31
   PubMed Web of Science ®Google Scholar
• Sloand E, Maciejewski JP, Tisdale J, et al. Intracellular Interferon-γ (IFN-γ) in circulating and marrow T cells detected by flow cytometry and the response to immunosuppressive therapy in patients with aplastic anemia. Blood 2002;100:3129-35
   Web of Science ®Google Scholar
• Dufour C, Ferretti E, Bagnasco F, Marrow Failure Study Group of the AIEOP. Changes in cytokine profile pre- and post-immunosuppression in acquired aplastic anemia. Haematologica 2009;94(12):1743-7
   PubMedGoogle Scholar
• Zeng W, Maciejewski JP, Chen G, Young NS. Limited heterogeneity of T-cell receptor VB usage in aplastic anemia. J Clin Invest 2001;108:765-73
   PubMed Web of Science ®Google Scholar
• Kook H, Risitano AM, Zeng W, et al. Changes in T-cell receptor VB repertoire in aplastic anemia: effects of different immunosuppressive regimens. Blood 2002;99:3668-75
   PubMed Web of Science ®Google Scholar
• Risitano AM, Kook H, Zeng W, et al. Oligoclonal and polyclonal CD4 and CD8 lymphocytes in aplastic anemia and paroxysmal nocturnal hemoglobinuria measured by Vβ CDR3 spectratyping and flow cytometry. Blood 2002;100:178-83
   PubMed Web of Science ®Google Scholar
• Nakao S, Takami A, Takamatsu H, et al. Isolation of a T-cell clone showing HLA-DRB1*0405-restricted cytotoxicity for hematopoietic cells in a patient with aplastic anemia. Blood 1997;89:3691-9
   PubMed Web of Science ®Google Scholar
• Maciejewski JP, Selleri C, Sato T, et al. A severe and consistent deficit in marrow and circulating primitive hematopoietic cells (long-term culture-initiating cells) in acquired aplastic anemia. Blood 1996;88:1983-91
   PubMed Web of Science ®Google Scholar
• Zeng W, Chen G, Kajigaya S, et al. Gene expression profiling in CD34 cells to identify differences between aplastic anemia patients and healthy volunteers. Blood 2004;103:325-32
   PubMed Web of Science ®Google Scholar
• Champlin R, Ho W, Gale RP. Antithymocyte globulin treatment in patients with aplastic anemia: a prospective randomized trial. N Engl J Med 1993;308:113-18
   Google Scholar
• Frickhofen N, Kaltwasser JP, Schrezenmeier H, et al. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. N Engl J Med 1991;324:1297-304
   PubMed Web of Science ®Google Scholar
• Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H; German Aplastic Anemia Study Group. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 2003;101:1236-42
   PubMed Web of Science ®Google Scholar
• Risitano AM. Immunosuppressive therapies in the management of acquired immune-mediated marrow failures. Curr Opin Hematol 2012;19(1):3-13
   PubMedGoogle Scholar
• Scheinberg P, Nunez O, Weinstein BP, et al. Horse versus Rabbit Antithymocyte Globulin in Acquired Aplastic Anemia. N Engl J Med 1997;365:430-8
   Google Scholar
• Pillow RP, Epstein RB, Buckner CD, et al. Treatment of bone-marrow failure by isogeneic marrow infusion. N Engl J Med 1966;275(2):94-7
   PubMedGoogle Scholar
• Hinterberger W, Rowlings PA, Hinterberger-Fischer M, et al. Results of transplanting bone marrow from genetically identical twins into patients with aplastic anemia. Ann Intern Med 1997;126(2):116-22
   PubMed Web of Science ®Google Scholar
• Thomas ED, Storb R, Fefer A, et al. Aplastic anaemia treated by marrow transplantation. Lancet 1972;1(7745):284-9
   PubMed Web of Science ®Google Scholar
• Storb R, Thomas ED, Buckner CD, et al. Allogeneic marrow grafting for treatment of aplastic anemia. Blood 1974;43(2):157-80
   PubMedGoogle Scholar
• Speck B, Zwaan FE, van Rood JJ, Eernisse JG. Allogeneic bone marrow transplantation in a patient with aplastic anemia using a phenotypically HL-A-identical unrelated donor. Transplantation 1973;16(1):24-8
   PubMedGoogle Scholar
• Lohrmann HP, Dietrich M, Goldmann SF, et al. Bone marrow transplantation for aplastic anaemia from a HL-A and MLC-identical unrelated donor. Blut 1975;31(6):347-54
   PubMedGoogle Scholar
• Hansen JA, Clift RA, Mickelson EM, et al. Marrow transplantation from donors other than HLA identical siblings. Hum Immunol 1981;2(1):31-40
   PubMedGoogle Scholar
• Bacigalupo A, Hows J, Gordon Smith EC, et al. Bone marrow transplantation for severe aplastic anemia from donors other than HLA identical siblings: a report of the BMT working party. Bone Marrow Transplant 1988;3:531
   PubMed Web of Science ®Google Scholar
• Hows J, Szydlo R, Anasetti C, et al. Unrelated donor marrow transplants for severe acquired aplastic anemia. Bone Marrow Transplant 1992;10(Suppl 1):102-6
   PubMedGoogle Scholar
• Camitta B, Ash R, Menitove J, et al. Bone marrow transplantation for children with severe aplastic anemia: use of donors other than HLA-identical siblings. Blood 1989;74:1852-7
   PubMedGoogle Scholar
• Maury S, Balere-Appert ML, Chir Z, et al. Unrelated stem cell transplantation for severe acquired aplastic anemia: improved outcome in the era of high-resolution HLA matching between donor and recipient. Haematologica 2007;92(5):589-96
   PubMedGoogle Scholar
• Viollier R, Socie G, Tichelli A, et al. Recent improvement in outcome of unrelated donor transplantation for aplastic anemia. Bone Marrow Transplant 2008;41(1):45-50
   PubMedGoogle Scholar
• Dezern AE, Luznik L, Fuchs EJ, et al. Post-transplantation cyclophosphamide for GVHD prophylaxis in severe aplastic anemia. Bone Marrow Transplant 2011;46(7):1012-13
   PubMedGoogle Scholar
• Kulasekararaj AG, Marsh JC. Management of the refractory aplastic anemia patient: what are the options? Hematology Am Soc Hematol Educ Program 2013;2013:87-94
   PubMedGoogle Scholar
• Peffault de Latour R, Rocha V, Socie G. Cord blood transplantation in aplastic anemia. Bone Marrow Transplant 2013;48(2):201-2
   PubMedGoogle Scholar
• Socié G. Allogeneic BM transplantation for the treatment of aplastic anemia: current results and expanding donor possibilities. Hematol Am Soc Hematol Educ Program 2013;2013:82-6
   PubMedGoogle Scholar
• Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood 2012;120(6):1185-96
   PubMed Web of Science ®Google Scholar
• Doney K, Leisenring W, Storb R, Appelbaum FR. Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy. Seattle Bone Marrow Transplant Team. Ann Intern Med 1997;126(2):107-15
   PubMedGoogle Scholar
• Marsh JC, Ball SE, Cavenagh J, et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol 2009;147(1):43-70
   PubMed Web of Science ®Google Scholar
• Locasciulli A, Oneto R, Bacigalupo A, et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2007;92(1):11-18
   PubMed Web of Science ®Google Scholar
• Maury S, Aljurf M. Management of adult patients older than 40 years refractory to at least one immunosuppressive course: HLA-identical sibling HSCT using fludarabine-based conditioning. Bone Marrow Transplant 2013;48(2):196-7
   PubMedGoogle Scholar
• Storb R, Prentice RL, Buckner CD, et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med 1983;308(6):302-7
   PubMedGoogle Scholar
• Champlin RE, Perez WS, Passweg JR, et al. Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood 2007;109(10):4582-5
   PubMed Web of Science ®Google Scholar
• Storb R, Etzioni R, Anasetti C, et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood 1994;84(3):941-9
   PubMed Web of Science ®Google Scholar
• Storb R, Leisenring W, Anasetti C, et al. Long-term follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulin. Blood 1997;89(10):3890-1
   PubMedGoogle Scholar
• Bacigalupo A, Socie G, Schrezenmeier H, et al. Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups. Haematologica 2012;97(8):1142-8
   PubMed Web of Science ®Google Scholar
• Schrezenmeier H, Passweg JR, Marsh JC, et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood 2007;110(4):1397-400
   PubMed Web of Science ®Google Scholar
• Storb R, Deeg HJ, Farewell V, et al. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood 1986;68(1):119-25
   PubMedGoogle Scholar
• Storb R, Leisenring W, Deeg HJ, et al. Long-term follow-up of a randomized trial of graft-versus-host disease prevention by methotrexate/cyclosporine versus methotrexate alone in patients given marrow grafts for severe aplastic anemia. Blood 1994;83(9):2749-50
   PubMedGoogle Scholar
• Locatelli F, Bruno B, Zecca M, et al. Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial. Blood 2000;96(5):1690-7
   PubMedGoogle Scholar
• Marsh JC, Gupta V, Lim Z, et al. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia. Blood 2011;118(8):2351-7
   PubMed Web of Science ®Google Scholar
• Socie G, Stone JV, Wingard JR, et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med 1999;341(1):14-21
   PubMedGoogle Scholar
• Deeg HJ, Leisenring W, Storb R, et al. Long-term outcome after marrow transplantation for severe aplastic anemia. Blood 1998;91(10):3637-45
   PubMed Web of Science ®Google Scholar
• Konopacki J, Porcher R, Robin M, et al. Long-term follow up after allogeneic stem cell transplantation in patients with severe aplastic anemia after cyclophosphamide plus antithymocyte globulin conditioning. Haematologica 2012;97(5):710-16
   PubMed Web of Science ®Google Scholar
• Doney K, Leisenring W, Storb R, Appelbaum FR. Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy. Seattle Bone Marrow Transplant Team. Ann Intern Med 1997;126(2):107-15
   PubMedGoogle Scholar
• Maury S, Bacigalupo A, Anderlini P, et al. Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen. Haematologica 2009;94(9):1312-15
   PubMed Web of Science ®Google Scholar
• Pulsipher MA, Young NS, Tolar J, et al. Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010. Biol Blood Marrow Transplant 2011;17(3):291-9
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Marsh JC. Unrelated donor search and unrelated donor transplantation in the adult aplastic anaemia patient aged 18-40 years without an HLA-identical sibling and failing immunosuppression. Bone Marrow Transplant 2013;48(2):198-200
   PubMedGoogle Scholar
• Lee SJ, Klein J, Haagenson M, et al. High resolution donor-recipient HLA matching contributes to the success of unrelated donor transplantation. Blood 2007;110:4576-83
   PubMed Web of Science ®Google Scholar
• Horan J, Wang T, Haagenson M, et al. Evaluation of HLA matching in unrelated hematopoietic stem cell transplantation for nonmalignant disorders. Blood 2012;120(14):2918-24
   PubMedGoogle Scholar
• Perez-Albuerne ED, Eapen M, Klein J, et al. Outcome of unrelated donor stem cell transplantation for children with severe aplastic anemia. Br J Haematol 2008;141:216-23
   PubMed Web of Science ®Google Scholar
• Eapen M, Horowitz MM. Alternative donor transplantation for aplastic anemia. Hematology Am SocHematol Educ Program 2010;2010:43-6
   PubMedGoogle Scholar
• Bacigalupo A, Locatelli F, Lanino E, et al. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party. Bone Marrow Transplant 2005;36(11):947-50
   PubMedGoogle Scholar
• Bacigalupo A, Socie G, Lanino E, et al. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA Working Party. Haematologica 2010;95(6):976-82
   PubMed Web of Science ®Google Scholar
• Kojima S, Matsuyama T, Kato S, et al. Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Blood 2002;100(3):799-803
   PubMed Web of Science ®Google Scholar
• Deeg HJ, Amylon ID, Harris RE, et al. Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation. Biol Blood Marrow Transplant 2001;7(4):208-15
   PubMed Web of Science ®Google Scholar
• Deeg HJ, O’Donnell M, Tolar J, et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood 2006;108(5):1485-91
   PubMed Web of Science ®Google Scholar
• Eapen M, Le Rademacher J, Antin JH, et al. Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia. Blood 2011;118(9):2618-21
   PubMed Web of Science ®Google Scholar
• Kennedy-Nasser AA, Leung KS, Mahajan A, et al. Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. Biol Blood Marrow Transplant 2006;12(12):1277-84
   PubMed Web of Science ®Google Scholar
• Yagasaki H, Takahashi Y, Hama A, et al. Comparison of matched-sibling donor BMT and unrelated donor BMT in children and adolescent with acquired severe aplastic anemia. Bone Marrow Transplant 2010;45(10):1508-13
   PubMed Web of Science ®Google Scholar
• Samarasinghe S, Steward C, Hiwarkar P, et al. Excellent outcome of matched unrelated donor transplantation in paediatric aplastic anaemia following failure with immunosuppressive therapy: a United Kingdom multicentre retrospective experience. Br J Haematol 2012;157(3):339-46
   PubMed Web of Science ®Google Scholar
• Peffault de Latour R, Purtill D, Ruggeri A, et al. Influence of nucleated cell dose on overall survival of unrelated cord blood transplantation for patients with severe acquired aplastic anemia: a study by EUROCORD and the aplastic anemia working party of the European group for blood and marrow transplantation. Biol Blood Marrow Transplant 2011;17(1):78-85
   PubMed Web of Science ®Google Scholar
• Kosaka Y, Yagasaki H, Sano K, et al. Prospective multicenter trial comparing repeated immunosuppressive therapy with stem-cell transplantation from an alternative donor as second-line treatment for children with severe and very severe aplastic anemia. Blood 2008;111(3):1054-9
   PubMed Web of Science ®Google Scholar
• Yamamoto H, Kato D, Uchida N, et al. Successful sustained engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with severe aplastic anemia. Blood 2011;117(11):3240-2
   PubMedGoogle Scholar
• Peffault de Latour R, Rocha V, Socie G. Cord blood transplantation in aplastic anemia. Bone Marrow Transplant 2013;48(2):201-2
   PubMedGoogle Scholar
• O’Donnell PV, Luznik L, Jones RJ, et al. Non-myeloablative bone marrow transplantation from partially mismatched related donor using post transplant cyclophosphamide. Biol Blood Marrow Transplant 2002;8:377-86
   PubMed Web of Science ®Google Scholar
• Ciceri F, Lupo-Stanghellini MT, Korthof ET. Haplo-identical transplantation in patients with acquired aplastic anemia. Bone Marrow Transplant 2013;48(2):183-5
   PubMedGoogle Scholar
• Brodsky RA, Luznik L, Bolanos-Meade J, et al. Reduced intensity HLA-haplo-identical BMT with post transplant cyclophosphamide in nonmalignant hematologic diseases. Blood Marrow Transplant 2008;42:523-7
   PubMed Web of Science ®Google Scholar
• Dezern AE, Luznik L, Fuchs EJ, et al. Post-transplantation cyclophosphamide for GVHD prophylaxis in severe aplastic anemia. Bone Marrow Transplant 2011;46(7):1012-13
   PubMedGoogle Scholar
• Clay J, Kulasekararaj A, Potter V, et al. Non-myeloablative peripheral blood haploidentical stem cell transplantation for refractory severe aplastic anemia. Biol Blood Marrow Transplant 2014; pii: S1083-8791(14)00395-4. [Epub ahead of print]
   PubMedGoogle Scholar
• Spellman SR, Eapen M, Logan BR, et al. A perspective on the selection of unrelated donors and cord blood units for transplantation. Blood 2012;120(2):259-65
   PubMed Web of Science ®Google Scholar
• Sangiolo D, Storb R, Deeg HJ, et al. Outcome of allogeneic hematopoietic cell transplantation from HLA-identical siblings for severe aplastic anemia in patients over 40 years of age. Biol Blood Marrow Transplant 2010;16(10):1411-18
   PubMed Web of Science ®Google Scholar
• Siegal D, Xu W, Sutherland R, et al. Graft-versus-host disease following marrow transplantation for aplastic anemia: different impact of two GVHD prevention strategies. Bone Marrow Transplant 2008;42(1):51-6
   PubMedGoogle Scholar
• Gupta V, Ball SE, Yi QL, et al. Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia. Biol Blood Marrow Transplant 2004;10(12):867-76
   PubMed Web of Science ®Google Scholar
• Kanda Y, Oshima K, Kako S, et al. In vivo T-cell depletion with alemtuzumab in allogeneic hematopoietic stem cell transplantation: combined results of two studies on aplastic anemia and HLA-mismatched haploidentical transplantation. Am J Hematol 2013;88(4):294-300
   PubMedGoogle Scholar
• Marsh JC, Pearce RM, Koh MB, British Society for Blood and Marrow Transplantation, Clinical Trials Committee. Retrospective study of alemtuzumab vs ATG-based conditioning without irradiation for unrelated and matched sibling donor transplants in acquired severe aplastic anemia: a study from the British Society for Blood and Marrow Transplantation. Bone Marrow Transplant 2014;49(1):42-8
   PubMed Web of Science ®Google Scholar
• Risitano AM. Paroxysmal Nocturnal Hemoglobinuria. In: Silverberg D, editor. Anemia: InTech. 2012
   Google Scholar
• Luzzatto L, Notaro R. 2003. Paroxysmal nocturnal hemoglobinuria. In: Handin RI, Lux SE, Stossel TP, eds. Blood, principles and practice of hematology (2nd ed.). Philadelphia: PA (USA): Lippincott Williams & Wilkins; p. 319-34
   Google Scholar
• Parker CJ, Ware RE. Paroxysmal nocturnal hemoglobinuria. In: Greer J, et al. editor. Wintrobe’s clinical hematology – 11th ed. Philadelphia: Lippincott Williams & Wilkins; 2003. p. 1203-21
   Google Scholar
• Miyata T, Takeda J, Iida Y, et al. The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. Science 1993;259:1318-20
   PubMed Web of Science ®Google Scholar
• Takeda J, Miyata T, Kawagoe K, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 1993;73:703-11
   PubMed Web of Science ®Google Scholar
• Nicholson-Weller A, March JP, Rosenfeld SI, et al. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc Natl Acad Sci USA 1983;80:5066-70
   PubMed Web of Science ®Google Scholar
• Holguin MH, Fredrick LR, Bernshaw NJ, et al. Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest 1989;84:7-17
   PubMed Web of Science ®Google Scholar
• Parker C, Omine M, Richards S, International PNH Interest Group. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 2005;106(12):3699-709
   PubMed Web of Science ®Google Scholar
• deLatour RP, Mary JY, Salanoubat C, et al. French Association of Young Hematologists. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood 2008;112:3099-106
   PubMedGoogle Scholar
• Lewis SM, Dacie JV. The aplastic anaemia–paroxysmal nocturnal haemoglobinuria syndrome. Br J Haematol 1967;13:236-51
   PubMed Web of Science ®Google Scholar
• Rotoli B, Luzzatto L. Paroxysmal nocturnal haemoglobinuria. Baillieres Clin Haematol 1989;2:113-38
   PubMedGoogle Scholar
• Luzzatto L, Bessler M, Rotoli B. Somatic mutations in paroxysmal nocturnal hemoglobinuria: a blessing in disguise? Cell 1997;88:1-4
   PubMed Web of Science ®Google Scholar
• Brodsky RA. How I treat paroxysmal nocturnal hemoglobinuria. Blood 2009;113(26):6522-7
   PubMed Web of Science ®Google Scholar
• Marotta S, Pagliuca S, Risitano AM. Current and future treatments for paroxysmal nocturnal hemoglobinuria. Treatment strategies. Blood Marrow Transplantation 2014;1(1):83-6
   Google Scholar
• Rother RP, Rollins SA, Mojcik CF, et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007;25:1256-64
   PubMed Web of Science ®Google Scholar
• Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006;355:1233-43
   PubMed Web of Science ®Google Scholar
• Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase III study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 2008;114:1840-7
   Google Scholar
• Hillmen P, Muus P, Duhrsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 2007;110:4123-8
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Hill A, Arnold LM, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood 2011;117:6786-92
   PubMed Web of Science ®Google Scholar
• Szer J, Deeg J, Witherspoon R, et al. Long-term survival after marrow transplantation for paroxysmal nocturnal hemoglobinuria with aplastic anemia. Ann Intern Med 1984;101:193-5
   PubMedGoogle Scholar
• Antin JH, Ginsburg D, Smith BR, et al. Bone marrow transplantation for paroxysmal nocturnal hemoglobinuria: eradication of the PNH clone and documentation of complete lymphohematopoietic engraftment. Blood 1985;66:1247-50
   PubMed Web of Science ®Google Scholar
• Bemba M, Guardiola P, Gardret L, et al. Bone marrow transplantation for paroxysmal nocturnal haemoglobinuria. Br J Haematol 1999;105:366-8
   PubMedGoogle Scholar
• Matos-Fernandez NA, AbouMourad YR, Caceres W, Kharfan-Dabaja MA. Current status of allogeneic hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria. Biol Blood Marrow Transplant 2009;15:656-61
   PubMed Web of Science ®Google Scholar
• Raiola AM, Van L, Lamparelli T, et al. Bone marrow transplantation for paroxysmal nocturnal hemoglobinuria. Haematologica 2000;85:59-62
   PubMed Web of Science ®Google Scholar
• Saso R, Marsh J, Cevreska L, et al. Bone marrow transplants for paroxysmal nocturnal haemoglobinuria. Br J Haematol 1999;105:366-8
   PubMedGoogle Scholar
• Santarone S, Bacigalupo A, Risitano AM, et al. Hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria: long-term results of a retrospective study on behalf of the GruppoItalianoTrapiantoMidollo Osseo (GITMO). Haematologica 2010;95:983-8
   PubMed Web of Science ®Google Scholar
• Peffault de Latour R, Schrezenmeier H, Bacigalupo A, et al. Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria. Haematologica 2012;97(11):1666-73
   PubMed Web of Science ®Google Scholar
• Takahashi Y, McCoy JP Jr, Carvallo C, et al. In vitro and in vivo evidence of PNH cell sensitivity to immune attack after nonmyeloablative allogeneic hematopoietic cell transplantation. Blood 2004;103:1383-90
   PubMed Web of Science ®Google Scholar
• Raiola AM, Van L, Lamparelli T, et al. Bone marrow transplantation for paroxysmal nocturnal hemoglobinuria. Haematologica 2000;85:59-62
   PubMed Web of Science ®Google Scholar
• Risitano AM, Notaro R, Pascariello C, et al. The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment. Blood 2012;119(26):6307-16
   PubMed Web of Science ®Google Scholar
• Risitano AM, Ricklin D, Huang Y, et al. Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood 2014;123(13):2094-101
   PubMed Web of Science ®Google Scholar
• Mastellos DC, Ricklin D, Yancopoulou D, et al. Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve treatment landscape. Expert Rev Hematol 2014; In press
   PubMedGoogle Scholar